Cirrhosis‐related hyponatremia and the role of tolvaptan

Publisher： John Wiley & Sons Inc

E-ISSN： 1872-034x|45|10|E163-E165

ISSN： 1386-6346

Source： HEPATOLOGY RESEARCH, Vol.45, Iss.10, 2015-10, pp. : E163-E165

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tolvaptan treatment for patients with decompensated cirrhosis and advanced hepatocellular carcinoma

By  

HEPATOLOGY RESEARCH, Vol. 45, Iss. 10, 2015-10 ,pp. : E161-E162

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tolvaptan in hospitalized cancer patients with hyponatremia: A double‐blind, randomized, placebo‐controlled clinical trial on efficacy and safety

By  

CANCER, Vol. 120, Iss. 5, 2014-03 ,pp. : 744-751

John Wiley & Sons Inc

Access to resources Recommend Favorite

Therapeutic effects of short‐ and intermediate‐term tolvaptan administration for refractory ascites in patients with advanced liver cirrhosis

By  

HEPATOLOGY RESEARCH, Vol. 45, Iss. 11, 2015-11 ,pp. : 1062-1070

John Wiley & Sons Inc

Access to resources Recommend Favorite

Increased serum C‐reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of tolvaptan in patients with liver cirrhosis

By  

HEPATOLOGY RESEARCH, Vol. 48, Iss. 3, 2018-02 ,pp. : E311-E319

John Wiley & Sons Inc

Access to resources Recommend Favorite

Hyponatremia: a significant factor in a poor prognosis for cirrhosis with Child A/B after variceal eradication

By  

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, Vol. 22, Iss. 10, 2015-10 ,pp. : 771-778

John Wiley & Sons Inc

Access to resources Recommend Favorite